製品名:2,3-Dichloropyrido[3,4-b]pyrazine

IUPAC Name:2,3-dichloropyrido[3,4-b]pyrazine

CAS番号:35251-99-1
分子式:C7H3Cl2N3
純度:95%+
カタログ番号:CM332598
分子量:200.02

包装単位 有効在庫 価格(USD) 数量
CM332598-100mg in stock Ȑŵ
CM332598-250mg in stock ǑȯǶ
CM332598-1g in stock ƃŵƃ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:35251-99-1
分子式:C7H3Cl2N3
融点:-
SMILESコード:ClC1=NC2=CN=CC=C2N=C1Cl
密度:
カタログ番号:CM332598
分子量:200.02
沸点:
MDL番号:MFCD19374272
保管方法:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Pyrazines
Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.
pyrazine,pyrazine price
if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

Column Infos

CVN424
In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products